Riluzole Patent Expiration
Riluzole was first introduced by Azurity Pharmaceuticals Inc
Riluzole Patents
Given below is the list of patents protecting Riluzole, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Tiglutik Kit | US8765150 | Riluzole aqueous suspensions | Mar 12, 2029 | Italfarmaco Sa |
| Exservan | US8603514 | Uniform films for rapid dissolve dosage form incorporating taste-masking compositions |
Apr 03, 2024
(Expired) | Aquestive |
| Exservan | US8765167 | Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions |
Feb 20, 2024
(Expired) | Aquestive |
| Rilutek | US5527814 | Use of 2-amino-6-(trifluoromethoxy)benzothiazole for obtaining a medicament for the treatment of amyotrophic lateral sclerosis |
Jun 18, 2013
(Expired) | Azurity |
A patent's expiry date may change depending upon legal activities going on that patent. Critical
activities like
abandoning of a patent, term extension of a patent or amendment of its claims can increase or
decrease the life of a
patent hence affecting its expiry date and in turn affecting the generic launch date of that
drug. Tracking these
ongoing activities on a patent application helps to keep an eye on the latest developments in
the patent process of
the drug which can give an idea of how early a drug's generic could be available. The next
section provides a list
of recent legal activities on Riluzole's patents.
Latest Legal Activities on Riluzole's Patents
Given below is the list recent legal activities going on the following patents of Riluzole.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 12th Year, Large Entity | 02 Jan, 2026 | US8765150 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 03 Jan, 2022 | US8765150 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 02 Jan, 2018 | US8765150 |
| Patent Issue Date Used in PTA Calculation Critical
| 01 Jul, 2014 | US8765150 |
| Recordation of Patent Grant Mailed Critical
| 01 Jul, 2014 | US8765150 |
| Email Notification Critical
| 12 Jun, 2014 | US8765150 |
| Issue Notification Mailed Critical
| 11 Jun, 2014 | US8765150 |
| Dispatch to FDC | 29 May, 2014 | US8765150 |
| Mail Miscellaneous Communication to Applicant | 27 May, 2014 | US8765150 |
| Printer Rush- No mailing | 27 May, 2014 | US8765150 |
Riluzole's Family Patents
Explore Our Curated Drug Screens
Clinical Trials
Recent Clinical Trials on Riluzole:
Sometimes companies keep conducting clinical trials even after the drug's approval to discover new formulations, methods of use, or new treatment indications, so they could file for additional patents or receive regulatory exclusivity extensions, such as pediatric exclusivity, potentially delaying generic competition. Based on these recent clinical trials, generic companies need to consider the potential for new intellectual property or regulatory hurdles. These strategic moves by the drug owner might delay generic substitution or lead to additional sales of the brand drug, even after patent expiry.
